Skip to main content

Advertisement

Table 1 Patients’ characteristics

From: Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer

Age, median (range) 74.1 (40.5–88.8)
Sex, n (%)
 Male 48 (90.6%)
 Female 5 (9.4%)
Primary or recurrence, n (%)
 Primary 42 (79.2%)
 Recurrence 11 (20.8%)
Recurrence within one year, n (%)
 Yes 9 (17.0%)
 No 44 (83.0%)
Tumor grade, n (%)
 Low 39 (73.6%)
 High 14 (26.4%)
T stage, n (%)
 pTa 42 (79.2%)
 pT1 11 (20.8%)
Number of tumor, n (%)
 Single 24 (45.3%)
 Multiple 29 (54.7%)
Tumor size, n (%)
  < 3 cm 46 (86.8%)
  ≥ 3 cm 7 (13.2%)
Concurrent CIS, n (%)
 Yes 2 (3.8%)
 No 51 (96.2%)
Immediate intravesical chemotherapy, n(%)
 Yes 51 (96.2%)
 No 2 (3.8%)
Additional adjuvant intravesical chemotherapy, n (%)
 Yes 12 (22.6%)
 No 41 (77.4%)
Second TUR, n (%)
 Yes 6 (11.5%)
 No 47 (88.5%)
  1. CIS carcinoma in situ, TUR transurethral resection